chemotherapy-induced myocardial injury
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Part one: (1) normal control group: no history of malignant tumor, no elevated tumor markers, and no definite abnormal findings on PET/CT imaging; (2) untreated cancer group: newly diagnosed malignant patients based on pathology within one month of PET/CT imaging, and no tumor-related treatment was initialed; (3) post-chemotherapy group: malignant patient with definite diagnosis who has completed chemotherapy, and the chemotherapy regimen contains at least one kind of adriamycin. Part two: (1) patients will be selected from the malignant patients admitted to Beijing Chaoyang Hospital from 2019.01 to 2020.12; (2) patients had newly diagnosed malignant tumors by pathology within one month of PET/CT imaging, without any tumor-related treatment; (3) patients were scheduled for chemotherapy according to the relevant guidelines and the chemotherapy regimen includes adriamycin drugs; (4) patients hve no previous history of heart disease, no clinical manifestations related to heart disease, and relevant examinations revealed no cardiovascular diseases; (5) patients have no other serious complications; (6) patients sign the informed consent and agreed to participate in the study.
Exclusion criteria
Exclusion criteria: All of the included patients in the two series have no the fololowing conditions: 1. The fasting time for PET/CT imaging was less than 12 hours; 2. Have a history of cardiovascular disease or other serious complications.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| LVEF;myocardial enzyme;Myocardial SUV;Uptake patterns of left ventricular; | — |
Countries
China
Contacts
Beijing Chao-Yang Hospital, Capital Medical University